BSX

#167
Boston Scientific Corp.
64.03 USD
+1.62%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
63.14
64.05
Jahresspanne
60.59
109.49
Tagesänderung
+1.62%
Monatliche Änderung
-7.44%
6 month change
-33.22%
Jahresänderung
-32.44%
Vorheriger Schlusskurs
63.01
Eröffnung
63.28
Bid
Ask
Tief
63.14
High
64.05
Volumen
345
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik
Vierteljährlich Jährlich
  • Market Capitalization 95.01 B
  • Employee 59 K
  • Founded 1979
  • CEO Michael F. Mahoney
  • Website www.bostonscientific.com
  • Headquarter Delaware, United States
  • FIGI BBG000C0LW92
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
49.15
Preis-Umsatz-Verhältnis
7.1

Boston Scientific Corporation

Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator. Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.

Nachrichten